humanized anti-egfr monoclonal antibody

Matuzumab (EMD 72000) is a humanized monoclonal antibody targeting EGFR with potential anticancer activity that blocks EGFR activation and downstream signaling for the study of non-small cell lung cancer.

Tomuzotuximab is a glycoengineered, humanized monoclonal antibody targeting the epidermal growth factor receptor (EGFR). Developed as an optimized derivative of cetuximab through glycan modification, the compound aims to enhance the clearance of EGFR-overexpressing tumor cells by boosting antibody-dependent cellular cytotoxicity (ADCC). It serves as an essential tool for investigating the synergy between receptor tyrosine kinase signaling blockade and immune effector enhancement.

Depatuxizumab is a humanised monoclonal antibody targeting EGFR with blood-brain barrier (BBB) permeability, capable of inhibiting the growth of xenograft tumours expressing mutant EGFR vIII and wild-type EGFR. It can be conjugated with the ADC molecule Depatuxizumab mafodotin for the study of glioblastoma (GBM) and head and neck squamous cell carcinoma (SCCHN).

Anti-DCBLD2/ESDN Antibody (FA19-1) is a humanized monoclonal antibody targeting Discoidin, CUB and LCCL domain-containing protein 2 (DCBLD2/ESDN/CLCP1). DCBLD2 is a type I transmembrane protein overexpressed in various malignancies (e.g., lung adenocarcinoma, glioma) and acts as a signal relay for growth factor signaling like EGFR. FA19-1 specifically binds to the extracellular domain of DCBLD2, blocking its mediated signaling—such as AKT activation or cisplatin-induced EMT—thereby inhibiting tumor cell migration, invasion, and distant metastasis.

MRG003 is an antibody-drug conjugate (ADC) composed of the humanized anti-EGFR IgG1 monoclonal antibody, Becotatug, coupled with MMAE. These components are linked through a valine-citrulline (valine-citrulline) connector, forming the Drug-Linker conjugate VcMMAE within the ADC.